AbbVie Inc. (ABBV) - Comprehensive Stock Analysis Report
📋 Investment SnapshotIs ABBV a buy right now? The 10-second read
Reason: Strong business, constructive setup. Expected Return is the upside to the analyst price target; full rationale is detailed below.
📌 Is ABBV a Buy right now?
According to Ultra Stock Analysis Pro, AbbVie Inc. (ABBV) reads WAIT for a new position (Signal Strength: 3/7 (last fired 2026-08-28, 28d ago)). The long-term fundamentals are strong (P/E: 74.5, Revenue Growth: +10.2%), while short-term technicals show a bullish trend (RSI: 59). Consider waiting for support confirmation near $267.69 before adding exposure.
For the latest stock analysis and interactive charts:
📊 Open ABBV Analysis ↗
⚡ QUICK DECISIONShould you buy, hold or wait on ABBV stock today?
- Reward:risk: 2.43:1 to the analyst target $289.69, against a stop at $253.90.
- Model timing: GREEN · BULLISH, WATCHING FOR ENTRY · ARMED.
- Stop reference: 2-3x the 14-day ATR of $5.22 below entry ($10.44–$15.66).
- Growth vs. valuation: revenue +10.2% YoY with a 40.0% operating margin, at a forward P/E of 18.8x.
- Wall Street: average target $289.69 (+9.6%) from 25 Buy, 5 Hold, 1 Sell ratings.
- Key levels: nearest support $261.33 (-1.1%), nearest resistance $267.69 (+1.3%).
💡 Why This Signal ExistsWhy does ABBV carry this rating?
ABBV carries a WAIT rating because the underlying business is solid (Investment Quality 66/100) and the trend is strong (ADX 25), but relative strength has lagged the S&P 500 over the past quarter and only a partial setup is building (Signal Strength 3/7). A breakout above $267.69 on improving volume would upgrade the signal toward BUY; a break below $261.33 would mark deeper weakness.
🎯 CONSENSUS HUDWhat is the Wall Street analyst consensus on ABBV?
The call itself, and the readings behind it. Details read supportive / caution / headwind.
Action plan
If you own it: the model holds no position.
If you don't: WAIT — Price is extended: -1.9% from the 52-week high (extended within 3%)
🎯 Intelligent Stop Loss Strategy
Current Price
$264.34
Buy Stop Loss
$253.90
Distance: 4%
Conservative 2.0x
Position Stop Loss
$253.90
Distance: 4%
Hybrid 2.00x
ATR 14 Day
$5.22
Volatility
ADX Strength
18.7
Weak/No Trend
New position - Standard stop loss levels
ADX: 20-25 = Emerging trend | 25-50 = Strong trend | 50+ = Very strong
🔮 FUTURE PRICE SCENARIOS (AI Forecast)Where could ABBV stock go over the next week?
To assist with risk management, here are the three most probable paths for ABBV over the next trading week:
🟢 The Bull Case (Probability: 42%)
If ABBV reclaims the $267.69 resistance level, algorithmic targets shift to $289.69. This move would likely be driven by continued sector rotation into Healthcare.
🔴 The Bear Case (Probability: 39%)
Failure to hold the $261.33 support level triggers a defensive stop-loss signal. In this scenario, the algorithm projects a slide toward the $245.03 liquidity zone (-7.3% from current price).
🟡 The Base Case (Sideways)
Given the current ADX of 19 (weak trend - consolidation likely), the most likely immediate outcome is consolidation between $261.33 and $267.69 until a volume catalyst occurs.
⚠️ These scenarios are algorithm-generated projections based on technical analysis, not financial advice. Past performance does not guarantee future results.
⚠️ RISK HUD — DEEP DIVEWhat are the biggest risks of buying ABBV now?
Five risk axes scored LOW / MODERATE / HIGH, then the mitigation that follows from them.
📊 BUY-SIDE HUDHow much ABBV should you own, and can you trade it at size?
Portfolio-management read: how much to own, what the historical edge is, and whether the position can be traded at size. Details below read supportive / caution / headwind; grey is context, not a verdict.
🎯 THE TWO VERDICTSShould you buy ABBV now, and should you hold it if you already own it?
Two questions, computed separately: the entry verdict never reads whether a position is open, and the position verdict never reads entry quality.
Price vs. its 50-day trend — EXTENDED
● fired ○ context, does not decide the badge
📏 ENTRY MATHWhat is the reward-to-risk on ABBV right now?
Reward is measured to the analyst target $289.69; risk to the 2x ATR entry stop at $253.90. Both legs are pre-trade, so the ratio means the same thing whether or not the model is holding.
Analyst figures are the consensus mean of the panel this report tracks. Other services poll a different set of analysts, so a target quoted elsewhere — including on our own live scanner — can sit a few percent either side of this one, and the reward leg moves with it.
A second analyst panel reads ABBV differently, and the two readings are materially different. The panel above averages $289.69 (2.43:1); an independent panel averages $278.61 (1.37:1). Neither is the correction of the other — they poll different analysts. Treat the reward leg as a range, not a point.
| Entry at | Price | Risk | Reward | R:R |
|---|---|---|---|---|
| Today at $264.34 | $264.34 | $10.44 | $25.35 | 2.43:1 |
Entry zones
📈 SELL-SIDE HUDIs ABBV stock overvalued or undervalued?
Research read: AbbVie Inc. · Healthcare · Drug Manufacturers - General. What the business is worth and where the Street stands. Details below read supportive / caution / headwind; grey is context, not a verdict.
🧭 Investment Quality vs. Entry QualityHow does ABBV's investment quality compare to its entry quality?
Two independent reads: how good the business is (fundamentals) vs. how stretched the price is against its recent range. Entry Quality is a mean-reversion score — it marks a stock down for trading near the top of its range. It is not the model's timing call, which is GREEN · BULLISH, WATCHING FOR ENTRY · ARMED and appears in the Consensus HUD above.
Strong on both. ABBV pairs a solid business with a constructive setup.
🧮 Factor AttributionWhat is actually driving ABBV's rating?
What is driving the view — every factor's signed contribution to one net score. Green adds to the bull case; red detracts.
| Factor | Contribution | Pts |
|---|---|---|
| Earnings Growth +290% YoY | +18 | |
| Trend EMA bullish, ADX 25 | +12 | |
| Valuation Fwd P/E 18.8, PEG 1.5 | +8 | |
| Revenue Growth +10% YoY | +7 | |
| Momentum RSI 51, MACD bullish | +5 | |
| Sentiment Slightly Bullish | +4 | |
| Relative Strength +0.7% vs benchmarks (3M) | +1 | |
| Volatility ATR 2.0% of price | +0 | |
| Profitability Margin 10%, ROE 0% | -5 |
Net Factor Score: +50 — Strongly bullish factor profile. This weighs the broad bull/bear case; the entry signal (Signal Strength) governs timing — a strong factor score can still read WAIT until a setup triggers.
🏆 Relative StrengthIs ABBV outperforming the S&P 500 and its sector?
The stock's return minus each benchmark's return. Positive = outperforming = leadership; negative = lagging. Relative strength is one of the most durable signals in quantitative research.
| Benchmark | 1-Mo | 3-Mo | 6-Mo |
|---|---|---|---|
| S&P 500 (SPY) | -0.4% | -1.0% | +7.0% |
| Healthcare (XLV) | +1.8% | -1.8% | +9.1% |
| Pharma (XPH) | +9.7% | +4.8% | +3.2% |
ABBV 3-month return: +5.1% · Leadership: MIXED — leads some benchmarks, lags others (see table)
🤖 ML ProbabilityWhat is the probability ABBV stock closes higher?
A gradient-boosted model's estimated probability that price closes higher over each horizon (directional estimate, not a guarantee).
📊 Valuation & Fundamentals vs Drug Manufacturers - General (10 peers)Is ABBV cheap or expensive versus its sector peers?
● Top 25% in sector ● Middle 50% ● Bottom 25% — each value colored by its rank among 10 Drug Manufacturers - General peers; "med" is the peer median.
⚔️ ABBV vs. Its Closest PeersHow does ABBV compare to JNJ and its other closest peers?
The closest business match first, then the nearest by market cap within Drug Manufacturers - General from the live sector screener. Industry classification alone is not enough — it files ABBV beside companies in a different line of business — so the direct competitor is seeded explicitly. Green marks the best reading in each row, red the worst.
| Metric | ABBV (this report) | JNJ | MRK | AMGN |
|---|---|---|---|---|
| Market Cap | $467.1B | $653.6B | $367.1B | $224.2B |
| Revenue Growth (YoY) | +10.2% | +6.6% | +5.1% | +9.5% |
| Forward P/E (FY2026E) | 18.8x | 23.5x | 54.3x | 18.0x |
| PEG Ratio (FY2026–FY2028E CAGR) | 1.45 | 2.29 | 1.38 | 3.13 |
| Operating Margin | 40.0% | 29.2% | -0.2% | 35.5% |
| Trend Strength (ADX) | 18.7 | 16.6 | 30.1 | 32.1 |
JNJ (Johnson & Johnson — closest business match), MRK (Merck & Co., Inc.), AMGN (Amgen Inc.). Peers marked “closest business match” come from the curated rival map; the rest are the nearest by market cap in the same industry. ADX is shown where recent price data is already on file for that peer.
🎯 ANALYST PRICE TARGETSHow high could ABBV go? The full target range
| Average Target: | $289.69 | High Target: | $315.00 |
| Current Price: | $264.34 | Low Target: | $235.00 |
| Upside to Average: | +9.6% | Number of Analysts: | 31 |
🔔 ANALYST RATING CHANGESHave analysts upgraded or downgraded ABBV recently?
Recent upgrades, downgrades, and price target changes (last 90 days)
| Firm | Action | From → To | Date |
|---|---|---|---|
| Wolfe Research | UPGRADE | Peer Perform → Outperform | Aug 13, 2026 |
| Erste Group | UPGRADE | Hold → Buy | Aug 05, 2026 |
News Sentiment (14-Day)What is the latest news sentiment on ABBV?
Overall Score: 3.9/10 - Slightly Bullish
Bullish Articles (Top 5 of 3)
- AI Could Give AbbVie (ABBV) a New Route to Long-Term Pipeline Growth
Insider Monkey • Sep 27AbbVie Inc. (NYSE:ABBV) and Iambic announced a multi-year collaboration to use Iambic’s AI platform to accelerate small-molecule drug discovery across...
Source: https://finance.yahoo.com/healthcare/articles/ai-could-abbvi... - What Does AbbVie (ABBV) Need To Prove With Its Latest Pipeline Moves?
Simply Wall St. • Sep 26AbbVie (NYSE:ABBV) acquired a stake in ADARx Pharmaceuticals during its IPO, gaining exposure to RNA interference drug candidates. The investment in A...
Source: https://finance.yahoo.com/healthcare/articles/does-abbvie-ab... - AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool • Sep 25AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition ...
Source: https://www.fool.com/coverage/better-buy/2026/09/25/abbvie-v...
📊 Sentiment Interpretation
The news sentiment is moderately bullish, showing generally positive coverage with some caution. Market perception appears favorable but not overwhelmingly positive. This neutral-to-positive sentiment suggests steady conditions without extreme optimism.
📊 Strategy Comparison: Conservative vs Adaptive
Both strategies analyzed independently. Conservative uses fixed 2.0x ATR stops. Adaptive adjusts stops based on position profit (tighter as profit grows).
Conservative Strategy
NO POSITIONFixed 2.0x ATR Stop Loss
Waiting for entry signal...
Entry Stop: $253.90 ({atr_multiplier}x ATR)
Backtest Results (Since 2018):
Past Win Rate
61%
Past Total Return
+51.8%
Max Drawdown
-15.3%
Avg Trade
+6.6%
Trades
18
Adaptive Strategy
NO POSITIONAdaptive ATR Stop Loss (1.0-2.75x)
Waiting for entry signal...
Entry Stop: $256.51 ({atr_multiplier}x ATR)
Backtest Results (Since 2018):
Past Win Rate
59%
Past Total Return
+55.5%
Max Drawdown
-15.2%
Avg Trade
+5.4%
Trades
22
EXECUTIVE SUMMARY - Essential MetricsWhat are the key metrics for ABBV stock?
| TECHNICAL METRICS | VALUE | FUNDAMENTAL METRICS | VALUE |
|---|---|---|---|
| Current Price | $264.34 | Market Cap | $467.1B |
| Past Win Rate (Backtest) | 61.1% (18 trades) | Forward P/E (FY2026E) | 18.8x |
| Past Total Return | +51.8% | Analyst Target | $289.69 |
| RSI / Trend Strength | 59 / 19 | Upside to Target | +9.6% |
| MACD Signal | Bullish | Revenue Growth | +10.2% |
| Profit Factor | 2.59 | Institutional Own. | 77.4% |
| Open Position | No open position | Analyst Ratings | 25 Buy / 5 Hold / 1 Sell |
🤖 ALGORITHMIC CONVICTION & METHODOLOGYHow is the ABBV rating calculated?
Why this rating?
The Ultra Stock Analysis algorithm has assigned a WAIT entry rating to ABBV based on a confluence of 3 distinct factors:
- Technical Momentum: The RSI (59) is currently in neutral range.
- Trend Strength: ADX at 19 indicates weak/consolidating conditions (<20). News sentiment is neutral (Slightly Bullish).
- Volatility Profile: The ATR ($5.22) indicates moderate volatility (2.0% of price), suggesting potential moves of 3.9%+ on breakouts.
📊 Confidence Interval:
Based on 7+ years of historical data, signals with this specific technical fingerprint have resulted in a positive return 61% of the time across 18 historical trades over a medium-term (months) hold period, with an average return of +6.6% per trade.
Firing now — EMA Trend Alignment (2) · Strong Trend (ADX > 25) (1).
Not firing: Valid Breakout, RSI Bullish Divergence, MACD Bullish Divergence, High Volume (>1.5×), RSI Oversold, Below Lower Bollinger, Volume Accumulation.
📊 How the score works — the full checklist, what each signal means, and why 3/7 can read low in an uptrend
Signal Strength is a tactical entry-timing score, not a trend or fundamentals grade. It only adds points from setups that flag a fresh reason to enter — breakouts, momentum divergences, and oversold/volume/volatility extremes. Trend direction and fundamentals are scored in their own sections above. A setup must reach 3+ points to register as a signal and 5+ for a strong BUY. Individual boxes below can be checked — a stacked EMA trend alone is worth 2 points — without crossing the 3-point bar; when that happens the registered Signal Strength stays at 3/7, meaning no new entry trigger today — not a bearish call.
| Signal | Pts | What it flags | Now |
|---|---|---|---|
| Valid Breakout | 3 | Close breaks above the 20-day high on >1.5× volume | ✗ |
| EMA Trend Alignment | 2 | EMA20 > EMA50 > EMA200 (stacked uptrend) | ✓ |
| RSI Bullish Divergence | 2 | Price firms while RSI was falling — a reversal setup | ✗ |
| MACD Bullish Divergence | 2 | Price firms while MACD was falling — a reversal setup | ✗ |
| Strong Trend (ADX > 25) | 1 | ADX > 25 confirming the stacked EMAs | ✓ |
| High Volume (>1.5×) | 1 | Volume surge confirming the move | ✗ |
| RSI Oversold | 1 | RSI < 30 — stretched to the downside (bounce setup) | ✗ |
| Below Lower Bollinger | 1 | Close below the lower band (mean-reversion setup) | ✗ |
| Volume Accumulation | 1 | Up-volume divergence — quiet accumulation | ✗ |
This is why ABBV can show a bullish EMA trend and solid fundamentals while Signal Strength reads 3/7: those are already-in-trend and value measures, whereas this score fires only on a new tactical setup (an oversold bounce, a divergence, or a high-volume breakout) — none of which is present on the latest bar.
❓ ABBV — Common Questions
— 5 answers, each drawn from the figures above
Every answer below is generated from the same figures as the report above, as of the data date on the cover.
📊 APPENDIX A - Complete Technical Indicators
Comprehensive technical data for quantitative analysis, grouped by what each indicator measures. Price leads; the three Bollinger bands sit together with the band position that reads them.
| Indicator | Value | Indicator | Value |
|---|---|---|---|
| Price & Volume | |||
| Current Price | $264.34 | Volume | 2.5M |
| Avg Volume | 5.1M | Beta | 0.28 |
| Trend | |||
| EMA 20 | $261.26 | EMA 50 | $255.26 |
| EMA 200 | $232.64 | VWAP | $264.31 |
| Trend Strength (ADX) | 18.65 | Distance from EMA 20 | +1.2% |
| Momentum | |||
| RSI (14) | 58.58 | MACD | 2.64 |
| MACD Signal | 2.34 | MACD Histogram | 0.30 |
| Stochastic %K | 79.91 | Stochastic %D | 84.00 |
| Bollinger Bands (20, 2σ) | |||
| Bollinger Upper | $269.91 | Bollinger Middle | $260.08 |
| Bollinger Lower | $250.25 | Band Position | 71.7% (0% = lower band, 100% = upper) |
| Volatility | |||
| ATR (14) | $5.22 | ATR as % of price | 2.0% |
| Signal | |||
| Confluence Score | 3/7 (last fired 2026-08-28, 28d ago) | Trade Signal | None in the last 30 days |
💼 APPENDIX B - Complete Fundamental Metrics
Comprehensive Fundamental Data for Financial Analysis
| Valuation Metrics | Performance | ||
|---|---|---|---|
| Market Cap | $467.1B | Revenue | $64.4B |
| Forward P/E (FY2026E) | 18.8 | Revenue Growth | +10.2% |
| Trailing P/E | 74.5 | Gross Margin | 72.8% |
| Price/Sales | 7.25 | Operating Margin | 40.0% |
| Price/Book | -78.70 | Profit Margin | 9.8% |
| PEG Ratio (FY2026–FY2028E CAGR) | 1.45 | ROE | 0.0% |
| Enterprise Value | $531.5B | Free Cash Flow | $16.9B |
| EPS (Forward) | $14.05 | Dividend Yield | 2.62% |
| 52-Week Range | $190.75 - $269.39 | ||
📈 APPENDIX C - Complete Trade History & Backtest Results
Comprehensive Trading Performance and Position Details
Backtest Performance Metrics
Recent Trade History (Last 10 Trades)
| Entry Date | Exit Date | Entry Price | Exit Price | Return % | Result |
|---|---|---|---|---|---|
| 2023-09-14 | 2023-10-05 | $138.52 | $132.94 | -4.03% | Loss |
| 2023-10-19 | 2023-11-14 | $132.51 | $125.72 | -5.13% | Loss |
| 2023-12-11 | 2024-04-16 | $137.72 | $150.82 | +9.51% | Win |
| 2024-04-26 | 2024-07-01 | $148.11 | $158.09 | +6.73% | Win |
| 2024-07-25 | 2024-11-13 | $170.59 | $160.79 | -5.74% | Loss |
| 2025-01-22 | 2025-04-10 | $161.21 | $165.98 | +2.96% | Win |
| 2025-09-11 | 2025-09-22 | $213.59 | $215.89 | +1.08% | Win |
| 2025-09-30 | 2025-11-05 | $224.57 | $211.76 | -5.70% | Loss |
| 2025-11-12 | 2026-01-14 | $227.84 | $216.76 | -4.86% | Loss |
| 2026-04-29 | 2026-07-17 | $202.45 | $254.49 | +25.71% | Win |
Summary: 18 total trades | Strategy: No Active Position
Run a Live Real-Time Scan of ABBV
This report is a snapshot through 2026-09-25. Get current technicals, fresh AI news sentiment, and up-to-the-minute stop-loss levels for ABBV — free, no signup.
▶ Run Live ABBV Analysis →